Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis

NCT ID: NCT01112722

Last Updated: 2016-12-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

363 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study will identify the efficacy of Apitox, purified honeybee toxin, in 330 patients with diagnosed osteoarthritis of the knee. The subjects will be evaluated for relief of pain using Western Ontario and McMaster Osteoarthritis Index (WOMAC) and Physician and Patient Global Assessments and primary efficacy measure of relief of pain and inflammation over a 12 week treatment period after randomization into the trial. Secondary efficacy is improvement of mobility Treatment effect will be compared in a 2-1 Apitox vs active control

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

feasibility and Site selection has been completed in the US and India

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis of the Knee

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

honeybee toxin Apitox pain inflammation osteoarthritis Apitoxin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Apitox, purified honeybee toxin, injections

active treatment drug 'Apitox, purified honeybee toxin, lyophilized in saline'

Group Type ACTIVE_COMPARATOR

Apitox, purified honeybee toxin, lyophilized in saline

Intervention Type BIOLOGICAL

intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections

histamine injection

the histamine injection produces a similar local effect of pain and erythema as the active drug

Group Type PLACEBO_COMPARATOR

histamine

Intervention Type BIOLOGICAL

imitates pain and erythema of honeybee venom

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Apitox, purified honeybee toxin, lyophilized in saline

intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections

Intervention Type BIOLOGICAL

histamine

imitates pain and erythema of honeybee venom

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Apitoxin in Korea

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* osteoarthritis of one or both knees
* on stable NSAID or none due to intolerance
* women either post menopausal or on stable birth control
* no clinically significant disease or or abnormal laboratory values
* signed informed consent, communicate effectively, understand and comply with all study requirements

Exclusion Criteria

* serious or unstable medical or psychological condition
* known sensitivity to honeybee venom, histamine or lidocaine
* history of asthma
* any clinically significant ECG abnormalities
* any clinically significant laboratory values OOR
* history of drug or alcohol abuse
* history of joint injury and forms of inflammatory arthritis
Minimum Eligible Age

30 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Apimeds, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Christopher M. H. Kim, M.D.

Role: STUDY_CHAIR

Apimeds, CEO

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Functional Research LLC

Gulf Shores, Alabama, United States

Site Status

Tucson Orthopaedic Institute

Tucson, Arizona, United States

Site Status

SC Clinical Research Inc.

Garden Grove, California, United States

Site Status

Axis Clinical Trials

Los Angeles, California, United States

Site Status

Westlake Medical Research

Thousand Oaks, California, United States

Site Status

SC Clinical Research Inc.

Upland, California, United States

Site Status

Schrock Orthopedics Research

Fort Lauderdale, Florida, United States

Site Status

AppleMed Research Inc.

Miami, Florida, United States

Site Status

Radiant Research Inc.

Pinellas Park, Florida, United States

Site Status

Beacon Clinical

Brockton, Massachusetts, United States

Site Status

Radiant Research Inc Columbus

Columbus, Ohio, United States

Site Status

Hillcrest Clinical Research

Olahoma City, Oklahoma, United States

Site Status

PMG Research of Knoxville

Knoxville, Tennessee, United States

Site Status

PMG Research of Knoxville

Knoxville, Tennessee, United States

Site Status

Tekton Research

Austin, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

01-13

Identifier Type: -

Identifier Source: org_study_id